Cytyc Cites FDA Warning Letter In Second Infringement Action Against TriPath
This article was originally published in The Gray Sheet
Executive Summary
TriPath's marketing claim that its AutoCyte PREP has results superior and not similar to conventional Pap smear testing "is particularly egregious because it attempts to mislead and confuse consumers about the efficacy and identity of the two products," competitor Cytyc, Inc. claims in a suit filed May 12 in Boston federal court.